Related Experiment Videos
Decrease of hypothalamic neuropeptide Y gene expression by vanadyl sulfate in streptozotocin-induced diabetic rats
1Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan, ROC.
Abstract:
In an attempt to elucidate the effect of vanadium compounds on the gene expression of neuropeptide Y (NPY), vanadyl sulfate (VOSO4) was orally administrated at the dose of 1 mg/kg body weight into streptozotocin-induced diabetic rats (STZ-diabetic rats) three times daily for 1 week. We found a marked lowering of plasma glucose with a significant decrease of food and water intake in these STZ-diabetic rats treated with VOSO4, although the weight gain was unaffected. The increase of hypothalamic NPY, both the mRNA level and peptide concentration, in STZ-diabetic rats was also reduced by this oral treatment of VOSO4. However, similar treatment of VOSO4 in normal rats failed to modify the feeding behavior and hypothalamic NPY gene expression. These data suggest that decrease of hypothalamic NPY gene expression by VOSO4 is related to the recovery of hyperphagia in diabetic rats lacking insulin.
Insights
Vanadyl sulfate (VOSO4) treatment lowered blood glucose and reduced neuropeptide Y (NPY) gene expression in diabetic rats. This suggests VOSO4 may help manage diabetic hyperphagia by impacting NPY levels.
Area of Science:
- Endocrinology
- Neuroscience
- Toxicology
Background:
- Diabetes mellitus is characterized by hyperglycemia and altered feeding behaviors.
- Neuropeptide Y (NPY) plays a crucial role in regulating appetite and energy balance.
- Vanadium compounds are being investigated for their potential therapeutic effects in metabolic disorders.
Purpose of the Study:
- To investigate the effect of vanadyl sulfate (VOSO4) on neuropeptide Y (NPY) gene expression in streptozotocin-induced diabetic rats.
- To determine if VOSO4 administration influences plasma glucose levels, food and water intake, and body weight in diabetic and normal rats.
Main Methods:
- Streptozotocin-induced diabetic rats and normal rats were orally administered vanadyl sulfate (VOSO4) at 1 mg/kg body weight, three times daily for one week.
- Plasma glucose levels, food and water intake, and body weight were monitored.
- Hypothalamic NPY mRNA levels and peptide concentrations were measured.
Main Results:
- VOSO4 treatment significantly lowered plasma glucose levels and reduced food and water intake in STZ-diabetic rats.
- The increase in hypothalamic NPY mRNA and peptide levels observed in STZ-diabetic rats was attenuated by VOSO4 treatment.
- VOSO4 administration did not affect feeding behavior or hypothalamic NPY gene expression in normal rats.
Conclusions:
- Vanadyl sulfate (VOSO4) administration can ameliorate hyperglycemia and hyperphagia in diabetic rats.
- The observed effects of VOSO4 in diabetic rats are associated with a decrease in hypothalamic NPY gene expression.
- These findings suggest that VOSO4 may be a potential therapeutic agent for managing metabolic disturbances, particularly hyperphagia, in diabetes by modulating NPY pathways.